Consultation on regulatory changes for tramadol

From Health Canada

Current status: Open

Opened on April 20, 2019 and will close on June 18, 2019.

You are invited to comment on a proposal to add tramadol to:

  • the Schedule I of the Controlled Drugs and Substances Act (CDSA)
  • the Schedule to the Narcotic Control Regulations (NCR)

Join in: how to participate

Review the proposed changes and the Regulatory Impact Analysis Statement in Canada Gazette, Part I.

Send us an email

Comment by email to hc.csd.regulatory.policy-politique.reglementaire.dsc.sc@canada.ca

Participate by mail:

Send your comments to the address in the contact section.

Consultation goals

Tramadol is an opioid analgesic. It is available by prescription to provide pain relief. Like other prescription opioids, tramadol can produce euphoria and dependence. It can also cause effects such as seizures and respiratory failure, especially when it is used problematically.

To help protect Canadians from the health and safety risks of improper opioid use, we are proposing to add tramadol to the CDSA and NCR. This will help to prevent it from being diverted for unauthorized use while keeping it available for valid medical and scientific purposes.

Related information

Contact us

Office of Legislative and Regulatory Affairs
Controlled Substances and Cannabis Branch
150 Tunney’s Pasture Driveway, Main Stats Building - 2605A
Ottawa ON K1A 0K9

Email: hc.csd.regulatory.policy-politique.reglementaire.dsc.sc@canada.ca

Report a problem or mistake on this page
Please select all that apply:

Thank you for your help!

You will not receive a reply. For enquiries, contact us.

Date modified: